Efficacy and safety of factor VIII inhibitor by-passing activity (FEIBA) in high thrombotic risk patients with acquired haemophilia (AH)

被引：0
|
作者：
Gamba, G. [1 ]
Montani, N. [1 ]
Trinchero, A. [1 ]
Pecci, A. [1 ]
Bertolino, G. P. [1 ]
Lodo, F. [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Internal Med, Haemophilia Ctr, I-27100 Pavia, Italy
来源：
HAEMOPHILIA | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [41] Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
    Tjonnfjord, Geir E.
    Holme, Pal Andre
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (04) : 527 - 531
  • [42] Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A
    van der Bom, J. G.
    Gouw, S. C.
    Rosendaal, F. R.
    HAEMOPHILIA, 2014, 20 (02) : E171 - E174
  • [43] Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy
    Ellsworth, Patrick
    Chen, Sheh-Li
    Key, Nigel
    Abajas, Yasmina
    Ma, Alice
    HAEMOPHILIA, 2021, 27 (01) : E147 - E150
  • [44] Patient and parent preferences for efficacy, inhibitor risk, safety, and infusion frequency associated with prophylactic Factor VIII treatment
    Mohamed, A. F.
    Lin, V. W.
    Posner, J. D.
    Epstein, J. D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 797 - 798
  • [45] PATIENT AND PARENT PREFERENCES FOR EFFICACY, INHIBITOR RISK, SAFETY, AND INFUSION FREQUENCY ASSOCIATED WITH PROPHYLACTIC FACTOR VIII TREATMENT
    Mohamed, Ateesha F.
    Posner, Joshua
    Epstein, Josh
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E44 - E44
  • [46] Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A
    Klamroth, Robert
    Gottstein, Saskia
    Orlovic, Marija
    Heinrichs, Christl
    THROMBOSIS RESEARCH, 2014, 134 : S38 - S42
  • [47] Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data
    Larson, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) : 145 - 146
  • [48] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [49] PERCUTANEUS TRANSLUMINAL ANGIOPLASTY (PTA) FOR AORTIC COARCTATION (COA) IN PATIENT WITH HEMOPHILIA A AND HIGH INHIBITORS TITRE USING FACTOR VIII INHIBITOR BYPASS ACTIVITY (FEIBA®)
    Giuffrida, G.
    Parrinello, N.
    Lombardo, R.
    Di Francesco, E.
    Cingari, R.
    Ussia, D.
    Triolo, A.
    Di Raimondo, F.
    HAEMATOLOGICA, 2013, 98 : 748 - 748
  • [50] SAFETY, EFFICACY AND INHIBITOR RISK OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) IN A COHORT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA-A
    BRAY, GL
    COURTER, S
    LYNES, M
    LEE, M
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1205 - 1205
12345